Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Been digging through some interesting penny stock setups that could deliver multibagger returns if the thesis plays out. The key here is looking beyond quick trades and actually finding companies with real business models that analysts think could moon over time.
First one catching my attention is Bionano Genomics. Gene editing is going to be huge over the next decade, and BNGO's Saphyr system is doing some legit work mapping genomes. They had 240 units installed by end of 2022, which was up 46% from the year before, and they're guiding for another 45% growth. Revenue growth isn't matching hardware growth yet, which is the concern, but here's the thing - insiders have been buying since mid-2023. You know what they say about insider buys. Analysts are calling 700% upside on this one, which is wild but worth tracking.
Then there's Nauticus Robotics. They're combining AI with robotics for subsea applications, which sounds like sci-fi but is actually pretty practical. They just landed a contract with Petrobras to test their autonomous underwater vehicle in Brazil. The ocean economy alone is valued at $2.5 trillion, and their tech could be crucial for offshore wind and rare earth mining. Stock is down over 70% since going public in 2021, but analysts see 150% upside from here. Not the craziest multibagger potential on this list, but solid if the thesis holds.
Last is Harpoon Therapeutics, which is a true penny stock under a dollar. They're working on using T-cells to treat hard-to-treat tumors, and they've got a decent pipeline with AbbVie backing their lead candidate through trials. Only problem is HPN217 is still in Phase 1, so we're talking years before any revenue. Stock got crushed - went from over $22 in 2021 down to nothing. But analysts still see 600% upside potential, and institutional ownership is solid at 65%.
With all three of these, the multibagger potential is real but so is the risk. You're betting on execution and market timing. These aren't plays for weak hands, but if you've got the patience and can handle volatility, there's some interesting setups here for 2023 and beyond.